Benefits Of Drinking Water: Tips And Tricks To Love Drinking Water

Read more

Battling And Beating Cancer – Leukemia and Leukemia Research With Dr Le Beau

Read more

Maude – Walter’s Crisis, Part 2 (Season 5, Episode 5) 2/2

Read more

Remedy For Anxiety

Read more

FAT GIRL FITNESS TIPS

I just found this health related video on YouTube … and thought you might enjoy it!

youtube.com/watch?v=h9dzNJuYLfk%3Fversion%3D3%26f%3Dvideos%26app%3Dyoutube_gdata

Tired of the same old you? Fancy getting fit? Follow this video and you’ll be in shape in no time! twitter.com Music used with permission from DFTBA records Driftless Pony Club – Legends of Archery visit dftba.com where you can buy the album!

Tell us what you think about this video in the comments below, or in the Battling For Health Community Forum!
credit-n.ru/zaymyi-next.html

Healthy Pregnancy, Healthy Baby: Healthy Food Choices

I just found this health related video on YouTube … and thought you might enjoy it!

youtube.com/watch?v=uPjLJt79qYU%3Fversion%3D3%26f%3Dvideos%26app%3Dyoutube_gdata

March of Dimes videos and DVDs are available for presentation on your closed-circuit TV, digital and/or on-demand systems. For licensing information, please contact productquestions@marchofdimes.com or 914-997-4781. www.marchofdimes.com Dr. Siobhan Dolan goes food shopping to talk about the essential nutrients pregnant women need, and provides tips to maintain a healthy pregnancy diet.

Tell us what you think about this video in the comments below, or in the Battling For Health Community Forum!
credit-n.ru/zaymyi-next.html

Health & Fitness Tips, OOTD, New Puppy

I just found this health related video on YouTube … and thought you might enjoy it!

youtube.com/watch?v=PcvHKNFYhWU%3Ff%3Dvideos%26app%3Dyoutube_gdata

My health & fitness tips, Outfit of the day, and my sis-in-law’s new puppy! CRAZY long video…. I know! But seriously, LOTS of things are combined in this one video. Hope you guys enjoy! 🙂 Become a fan! My Facebook page: www.facebook.com Vote for Gucci in the Bissel MVP contest! If he wins, my sis wins a large donation to the pet charity of her choice and Gucci’s picture will be on a Bissel box! bissell.promo.eprize.com Subscribe to my main channel: www.youtube.com /MakeupByTiffanyD Follow me on twitter for daily updates, pictures, and announcements: twitter.com Get my favorite makeup brushes here: www.tinyurl.com My stuff: Necklace: Tiffany & Co sterling bar longer Necklace: J. Crew Earrings: Tacori Gold beaded bracelet : It’s old :/ I have no idea Gold bracelet: Guess *This video was not sponsored by any brands mentioned

Tell us what you think about this video in the comments below, or in the Battling For Health Community Forum!
credit-n.ru/zaymyi-next.html

How to (lose weight) fast (I lost 30 pounds)

I just found this health related video on YouTube … and thought you might enjoy it!

youtube.com/watch?v=iz5T6XethMc%3Ff%3Dvideos%26app%3Dyoutube_gdata

www.howtoloseweightfastnodiet.com This is the story of how I lost 30 pounds. I hope this video is encouraging to some of you. Daniel etherdige. lose weight, diet, running, Want to Lose Weight &www.SmallStep.gov Feel Better? Get 100 Tips for a Healthy Lifestyle & Start Today!How To Lose WeightSimple Ways To Lose Weight From Your About Exercise Guide.exercise.about.com – -How to Lose Weight Fast – wikiHowwikiHow article about How to Lose Weight Fast. … To lose weight effectively, you need to stick to your weight loss plan religiously so as to see results. …www.wikihow.com/Lose-Weight-Fast – How To Lose Weight | eHow.comHow to Lose Weight. Figuring out how to lose weight is a challenge for many of us, particularly considering that the quickest path to weight loss is … www.ehow.com/how_4622_lose-weight.html – Lose Weight Group – Learn How To Lose Weight!Lose Weight Group » Complete, free losing weight website and community. We teach you how to lose weight and keep you motivated for real resultswww.loseweightgroup.com/ – Overweight and ObesityFDA along with other government agencies are helping citizens of the US lose weight in order to curb the ever growing trend of obesity in this country.www.fda.gov/loseweight/ How Can I Lose Weight Safely?Lots of people are unhappy with their present weight, but aren’t sure how to change it – or even if they need to. Get the facts on weight loss here.www.kidshealth.org/teen/question/dieting/lose_weight_safely.html – 50 Weight Loss …

Tell us what you think about this video in the comments below, or in the Battling For Health Community Forum!
credit-n.ru/zaymyi-next.html

UMass University Without Walls – UWW Student Profiles

I just found this health related video on YouTube … and thought you might enjoy it!

youtube.com/watch?v=nyL9OwfX2kk%3Ff%3Dvideos%26app%3Dyoutube_gdata

Through the University of Massachusetts Amherst University Without Walls, you can fit completing your college degree into your life and work by taking courses offered weeknights, weekends, online and blended (some live, some online). UWW will help you accelerate earning your degree with stimulating courses, a generous transfer credit policy, and the opportunity to earn credit for learning gained from your life, training, and work experience. Youll emerge with your diploma in hand, more confident, more knowledgeable in your field, a better problem-solver, with renewed professional and personal goals. People are at the heart of UWW. Youll find students supporting each other, sharing ideas and experiences. Youll work closely with a UWW advisor who teaches your UWW courses, holds a doctoral degree, and has years of experience guiding adult learners. A faculty sponsor specializing in your area of interest will review your plans and recommend appropriate courses. Browse our website to learn more about UWW’s nearly 40 years of helping people like you finish their first undergraduate degree at our nationally recognized research university. Then, when youre ready to apply, download your application. Were looking forward to hearing from you, so feel free to email uww@uww.umass.edu or call 413.545.1378. Were here to help!

Tell us what you think about this video in the comments below, or in the Battling For Health Community Forum!
credit-n.ru/zaymyi-next.html

Baba Ramdev – Yoga To Increase Sperm Count In Men – English – Yoga Health Fitness

I just found this health related video on YouTube … and thought you might enjoy it!

youtube.com/watch?v=D5Dy72zagGI%3Ff%3Dvideos%26app%3Dyoutube_gdata

Watch Baba Ramdev – Yoga To Increase Sperm Count In Men – English – Yoga Health Fitness. This video is designed to help childless couples. Infertility is a problem that is on the rise and needs to be dealt with significance. Yoga techniques help you to redirect your attention to focus on yourself, your movement and your breathing. All of these elements merge to help you mitigate stress, feel more in tune with your body and facilitate to restore and balance out your body’s systems. This is exactly why many infertile couples have found yoga to be helpful for them. Click on www.rajshri.com to watch more Baba Ramdev Yoga videos and bring fitness and spirituality into your lives.

Tell us what you think about this video in the comments below, or in the Battling For Health Community Forum!
credit-n.ru/zaymyi-next.html

Hot Women Are Bad For Your Health (Study)

I just found this health related video on YouTube … and thought you might enjoy it!

youtube.com/watch?v=6M7C56zrfkM%3Ff%3Dvideos%26app%3Dyoutube_gdata

New TYT Facebook Page(!): www.facebook.com Don’t forget to check out Ana’s blog at: www.examiner.com Follow us on Twitter: twitter.com TYT Network (new WTF?! channel): www.youtube.com Check Out TYT Interviews www.youtube.com Watch more at www.theyoungturks.com

Tell us what you think about this video in the comments below, or in the Battling For Health Community Forum!
credit-n.ru/zaymyi-next.html

The Multiple Sclerosis Society of Canada, Quebec Division, Pays Tribute to Three Quebecers at the Opal Awards Dinner

MONTREAL, QUEBEC–(CCNMatthews – March 21, 2006) – The fourth Opal Awards Dinner, named for Evelyn Opal, the founder of the Multiple Sclerosis Society of Canada (MSSC), was held on Wednesday, March 1st, at the Sheraton Centre in Montreal. This prestigious awards ceremony pays tribute to the outstanding achievements and social commitment of three Quebecers. This year’s Opal Awards Dinner raised $451,100 in donations and services for the Multiple Sclerosis Society of Canada, Quebec Division. The money will be used to support research and services for people with multiple sclerosis and their families.

Robert E. Brown, President and CEO of CAE Inc., received the highest distinction of the evening, the Grand Merit Opal Award, for his career achievements and philanthropy.

The Opal Ambassador Award was presented to Robert Gervais, President and CEO of Pre2Post Inc., for his commitment to the MSSC. He has been a member of the MS Leadership Awards selection committee since 2002 and currently chairs this committee. It is because of Robert Gervais that the MSSC has been able to expand its visibility within the business community.

Nathalie Brouard, a Partner, Tax Services with PricewaterhouseCoopers LLP, received the Tribute Opal Award in acknowledgement of her courage and leadership. A volunteer with the MSSC since 1998, Nathalie Brouard formed what has become the number one team in the Super Cities WALK for MS, raising over $110,000 to fight the devastating effects of multiple sclerosis.

Multiple sclerosis is the most widespread neurological disorder among young adults in Canada. It mainly strikes between the ages of 15 and 40 and there is no cure. Some 12,000 Quebecers have MS.

For more information on the Multiple Sclerosis Society of Canada, Quebec Division, see the Web site at www.mssociety.ca/qc .

A division of the Multiple Sclerosis Society of Canada – Registered Charitable Organization No. 10490 2523 RR0001

Source and Photo will be available on CP picture wire.

MULTIMEDIA AVAILABLE:

www.ccnmatthews.com/em/1111

CONTACT INFORMATION
Multiple Sclerosis Society of Canada, Quebec Division
Isabelle Laplante
Communications Coordinator
(514) 849-7591 or 1 800 268-7582
isabelle.laplante@mssociety.ca

FDA Advisers Endorse Return of Multiple Sclerosis Drug

03.08.06, 12:00 AM ET

WEDNESDAY, March 8 (HealthDay News) — A U.S. Food and Drug Administration advisory panel voted unanimously Wednesday to allow the promising but controversial multiple sclerosis drug Tysabri back on the market.

The advisers continued to discuss certain controls on who could use the drug, which has been linked to a rare but potentially fatal brain infection. The panel members agreed to a manufacturer plan for a mandatory patient registry; they were scheduled to decide later in the day who would be allowed to enroll in the registry, and how tightly drug use would be limited, the Associated Press reported.

While the full FDA generally follows the recommendations of its advisory panels, it is not required to do so. The agency is expected to render its final decision on the drug by the end of the month.

Physicians and MS patients alike were heartened by the decision, which came during the second day of two days of deliberations.

“Tysabri is a very important step forward despite the fact that there are some concerns and limitations concerning its safety, but the safety risk at the moment, in the range of about one in 1,000, is probably well worth taking for patients with more severe or unstable disease,” said Dr. Joseph Herbert, director of the Multiple Sclerosis Care Center and chief of neurology at New York University/Hospital for Joint Diseases in New York City.

“Patients with rapidly progressive or aggressive MS are probably at far greater risk because of the disease than they are from a potential rare side effect of the drug,” Herbert said.

MS patient and attorney Karen Miller, 49, told the committee that Tysabri “is as close as it comes” to a miracle drug. Miller credited the drug with a renewed ability to ride her bike, wash her windows and run daily errands, the AP said.

“I am at the end of my road, in terms of what I can take. I want it to be my choice,” another MS patient, Barbara Crooks, 48, told the news service.

Tysabri’s manufacturers, Biogen Idec Inc. and Elan Corp, pulled the drug off the market in February 2005 after three patients taking it developed progressive multifocal leucoencephalopathy (PML), a progressive, neurodegenerative disease. Two of those patients died.

The removal took place just three months after the FDA had granted accelerated approval of the drug for the treatment of relapsing forms of MS.

In February, the FDA announced that Biogen and Elan could resume clinical trials for MS patients who were previously treated with the drug under an investigational study.

According to the National Institute of Neurological Disorders and Stroke, multiple sclerosis is an unpredictable disease of the central nervous system that can range from relatively benign to somewhat disabling to devastating. Most MS patients experience their first symptoms between the ages of 20 and 40, and most suffer muscle weakness in their extremities and difficulty with coordination and balance. These symptoms may be bad enough to hamper walking or even standing; in worst cases, MS can produce partial or complete paralysis.

Tysabri is a monoclonal antibody, engineered to attach itself to white blood cells called lymphocytes and prevent them from entering the brain, where they do damage that causes the disabling symptoms of MS. Tysabri had also been used to treat Crohn’s disease.

One of the biggest issues in bringing the drug back to market is what kind of risk-management plan should be implemented. An initial plan submitted to the FDA by the manufacturers was considered insufficient.

“There’s no question with this kind of essentially lethal risk that there is going to have to be some kind of risk-management program,” Dr. Robert Temple, director of the FDA’s Center for Drug Evaluation and Research, said at a Tuesday news conference.

Other features of a risk-management plan could include restrictions on who gets the drug, administering the drug at a registered infusion center, and monitoring all patients on the drug for at least five years. The drug may be restricted only to individuals with more severe forms of the disease, patients who have failed other therapies, and patients who are not taking other immunosuppressants.

“The three cases that did develop PML were all patients who were on other immune modulator drugs,” Herbert noted. “If we use Tysabri judiciously and as a monotherapy, it is possible that the risk will turn out to be lower than we imagine.”

Tysabri is only the second prescription drug to be returned to the market after being taken off. The other was Lotronex, used for irritable bowel syndrome, which was withdrawn in 2000 but allowed back on the market two years later.

“Lotronex was a unique drug with value for some people,” Temple said. “The drugs that disappear permanently tend to be drugs that tend to have substitutes.”

More information

Find out more about Tysabri at the U.S. Food and Drug Administration.

Source

© Forbes.com Inc.™ All Rights Reserved

No shortage of methadone say addiction treatment officials

Last updated Mar 14 2006 09:53 AM EST
CBC News

Methadone treatment centres across Ontario are assuring their patients that there is no shortage of the drug, despite recent fears clinics would run out after two major suppliers were shut down.

Monday was the deadline for two Kitchener-based suppliers to stop shipping methadone to clinics across the province, including to those in Toronto.

The Ontario College of Pharmacists ordered them to cease the shipments after accusing the suppliers of professional misconduct for sending the drug to clinics without appropriate supervision.

Methadone is a drug that is given to patients suffering narcotic addictions. It’s considered the most effective way to treat heroin addiction.

On Tuesday, the Ontario Addiction Treatment Centres (OATC) said there is still an adequate supply of methadone available.

“Published media reports in recent days have indicated that there might be a shortage of methadone for OATC patients,” says a message posted on the OATC website.

“This is not the case. Your methadone prescription will continue to be available as usual.”

OTAC supplies daily doses of methadone to 2,000 people across the province.

Source

Copyright © CBC 2006

Genetic Technologies Reports Breakthrough in the Genetic Basis of Drug Addiction

3/14/2006 9:24:00 AM EST

Genetic Technologies Limited (“GTG”) (Nasdaq:GENE) (ASX:GTG) is pleased to refer to a “breaking news” item released in London yesterday by BBC News. BBC reported a significant breakthrough had been made in understanding the genetic basis of cocaine addiction, quoting a scientific paper just published online by the prestigious Proceedings of the National Academy of Science (“PNAS”).

The report announced a genetic variation had been identified which could significantly increase the risk of an individual developing cocaine addiction or dependence. The discovery also validates the logic of a new basis for the design and use of novel drugs to treat cocaine abuse in the future.

The BBC article stated that this research was funded by the British Medical Research Council.

What is especially relevant to GTG stockholders is that this research was in fact co-funded by GTG, that the genetic variations identified by this project are non-coding, that new patents have just been filed on the relevance of these genetic variations to cocaine addition and that GTG has secured world-wide exclusive rights to commercialize these new discoveries. Indeed, this whole project arose from the foresight of King’s College London, who took a license to the GTG non-coding patents in 2004.

This project is yet another example of the original GTG non-coding patents today spawning new research, new discoveries and new patents and creating new opportunities for GTG into the future.

By way of further background information, the UN Office for Drug Control estimates the number of illegal drug users now exceeds 150 million worldwide. However, other studies suggest this is an under-estimate. Until now, the global pharmaceutical industry has not made treatment of substance abuse a priority. The current market is estimated to exceed US$1.1 billion, and is expected to grow to US$1.3 billion by 2008. Industry experts see this market as having great potential. It is also an area where fundamental patents are likely to prove extremely valuable, especially when combined with new genetic testing methods (genotyping), which will permit cheap and efficient whole genome scanning for susceptibility to cocaine addition.

About Genetic Technologies Limited

Genetic Technologies was an early pioneer in recognizing important new applications for “non-coding” DNA (DeoxyriboNucleic Acid). The Company has since been granted patents in 24 countries around the world, securing intellectual property rights for particular uses of non-coding DNA in genetic analysis and gene mapping across all genes in all multicellular species. Its three-pronged business strategy includes: 1) the global commercialization of its patents through an active licensing program; 2) the expansion of its dominant commercial genetic testing business in Australia; and, 3) the commercialization of its various research and development projects aimed at generating further intellectual property of global commercial significance.

This announcement may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933 and Section 21E of the U.S. Securities Exchange Act of 1934 with respect to the financial condition, results and business achievements/performance of Genetic Technologies Limited and certain of the plans and objectives of its management. These statements are statements that are not historical facts. Words such as “should,” “expects,” “anticipates,” “estimates,” “believes” or similar expressions, as they relate to Genetic Technologies Limited, are intended to identify forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect Genetic Technologies’ current expectations and assumptions as to future events and circumstances that may not prove accurate. There is no guarantee that the expected events, trends or results will actually occur. Any changes in such assumptions or expectations could cause actual results to differ materially from current expectations.

CONTACT:
Genetic Technologies Limited Dr. Mervyn Jacobson or Tom Howitt, +61-3-9415-1135 tom.howitt@gtg.com.au www.gtg.com.au or Investor Relations Contacts: Lippert/Heilshorn & Associates Kim Sutton Golodetz / Lisa Lindberg, 212-838-3777 kgolodetz@lhai.com / llindberg@lhai.com or Bruce Voss, 310-691-7100 bvoss@lhai.com www.lhai.com

Source
© 2006 Genetic Engineering News, All Rights Reserved

Clinical depression is a state of sadness or melancholia

Clinical depression is a state of sadness or melancholia that has advanced to the point of being disruptive to an individual’s social functioning and/or activities of daily living. The diagnosis may be applied when an individual meets a sufficient number of the symptomatic criteria for the depression spectrum as suggested in the DSM-IV-TR or ICD-9/10. An individual is often seen to suffer from what is termed a “clinical depression” without fully meeting the various criteria advanced for a specific diagnosis on the depression spectrum. There is an ongoing debate regarding the relative importance of genetic or environmental factors, or gross brain problems versus psychosocial functioning.

Although a mood characterized by sadness is often colloquially referred to as depression, clinical depression is something more than just a temporary state of sadness. Symptoms lasting two weeks or longer, and of a severity that begins to interfere with typical social functioning and/or activities of daily living, are considered to constitute clinical depression.

Clinical depression was originally considered to be a “chemical imbalance” in transmitters in the brain, a theory based on observations made in the 1950s of the effects of reserpine and isoniazid in altering monoamine neurotransmitter levels and affecting depressive symptoms [1]. Subsequent antidepressants have also been found to alter monoamine levels, particularly of serotonin and noradrenaline [2]. Despite a growing body of evidence suggesting otherwise, it is still a commonly held belief that depression is only a chemical imbalance. This idea is often promoted in pharmaceutical advertising, and perpetuated in everyday discussions. Despite this reliance on “common wisdom”, recent research and commentary has begun to address depression as an issue broader than this.

Clinical depression affects about 16%[3] of the population on at least one occasion in their lives. The mean age of onset, from a number of studies, is in the late 20s. About twice as many females as males report or receive treatment for clinical depression, though this imbalance is shrinking over the course of recent history; this difference seems to completely disappear after the age of 50 – 55, when most females have passed the end of menopause. Clinical depression is currently the leading cause of disability in the US as well as other countries, and is expected to become the second leading cause of disability worldwide (after heart disease) by the year 2020, according to the World Health Organization[4].

On a historical note, the modern idea of depression appears similar to the much older concept of melancholia. The name melancholia derives from ‘black bile’, one of the ‘four humours’ postulated by Galen.

The Ebers papyrus (ca 1550 BC) contains a short description of clinical depression. Though full of incantations and foul applications meant to turn away disease-causing demons and other superstition, it also evinces a long tradition of empirical practice and observation.

Source